ANTX vs ENTA vs CRL vs MEDP vs IQV vs JPM

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus -3. 4% for Enanta Pharmaceuticals, Inc. (ENTA). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AN2 Therapeutics, Inc. (ANTX) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus Medpace Holdings, Inc. at 30. 6x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Medpace Holdings, Inc. 's 0. 86x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -75. 0% for Enanta Pharmaceuticals, Inc. (ENTA). Over 10 years, the gap is even starker: MEDP returned +1582% versus ENTA's -48. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AN2 Therapeutics, Inc.

(ANTX) is the lower-risk stock at 0. 42β versus Charles River Laboratories International, Inc. 's 1. 39β — meaning CRL is approximately 228% more volatile than ANTX relative to the S&P 500. On balance sheet safety, Medpace Holdings, Inc. (MEDP) carries a lower debt/equity ratio of 55% versus 3% for Enanta Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus -3. 4% for Enanta Pharmaceuticals, Inc. (ENTA). On earnings-per-share growth, the picture is similar: AN2 Therapeutics, Inc. grew EPS 32. 6% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -125. 4% for Enanta Pharmaceuticals, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -130. 7% for ENTA. At the gross margin level — before operating expenses — ENTA leads at 93. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Medpace Holdings, Inc. 's 0. 86x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 2x forward P/E versus 27. 5x for Medpace Holdings, Inc. — 13. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ENTA: 305. 0% to $48. 20.

In this comparison, JPM (1.

9% yield) pays a dividend. ANTX, ENTA, CRL, MEDP, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 04), +1582% 10Y return). Both have compounded well over 10 years (MEDP: +1582%, ENTA: -48. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ANTX (Healthcare) and ENTA (Healthcare) and CRL (Healthcare) and MEDP (Healthcare) and IQV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ANTX is a small-cap quality compounder stock; ENTA is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; IQV is a mid-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while ANTX, ENTA, CRL, MEDP, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.